Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease
| Status: | Archived |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease, Cardiology, Anemia |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Hematology, Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | May 2008 |
| End Date: | December 2011 |
A Study to Evaluate the Effect of the Treatment of Anemia on Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease
This study examines patients with chronic kidney disease-related anemia and measures changes
in the metabolism of the heart using FDG/PET scanning, before and 6 months after their
health-care provider has initiated anemia management therapy with the FDA-approved drug
darbepoetin alfa (Aranesp), which is approved for chronic kidney disease-related anemia.
The investigators hypothesize that the heart has abnormal metabolism with the anemia of
chronic kidney disease but this improves after correction of this anemia with darbepoetin
alfa.
We found this trial at
1
site
Click here to add this to my saved trials
